J&J signs voluntary U.S. government deal: tariff exemption, TrumpRx access and $55 billion investment pledge

Johnson & Johnson reached a voluntary agreement with the Trump administration that exempts its pharmaceutical products from U.S. tariffs in return for wider patient access. The company is joining the TrumpRx.gov direct-to-patient platform and committed to Medicaid pricing comparable to other developed countries. The deal also reaffirms a $55 billion U.S. investment in manufacturing, R&D and technology through early 2029, and the company says specific terms remain confidential.

• Pharmaceutical products receive an exemption from U.S. tariffs
• Participation in TrumpRx.gov, where patients can buy medicines at discounted prices
• Total U.S. investment of $55 billion in manufacturing, R&D and technology by early 2029
• Two new U.S. plants announced: a cell therapy site in Pennsylvania and a drug product site in North Carolina